机构:[1]Department of Orthopedics, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118[2]Department of Orthopedics, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650000外科科室骨科昆明医科大学附属第一医院[3]Department of Pharmacy, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118[4]Department of Radiology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650101, P.R. China
Osteosarcoma (OS) is the most common type of primary bone tumor in children and adolescents and has been associated with a high degree of malignancy, early metastasis, rapid progression and poor prognosis. However, the use of adjuvant chemotherapy improves the prognosis of patients with OS. OS chemotherapy is based primarily on the use of adriamycin, cisplatin (DDP), methotrexate (MTX), ifosfamide (IFO), epirubicin (EPI) and other drugs. Previous studies have revealed that the survival rate for patients with OS appears to have plateaued: 5-year survival rates remain close to 60%, even with the use of combined chemotherapy. The most limiting factors include complications and fatal toxicity associated with chemotherapy agents, particularly high-dose MTX (HD-MTX), for which high toxicity and great individual variation in responses have been observed. Docetaxel (TXT) is a representative member of the relatively recently developed taxane class of drugs, which function to inhibit OS cell proliferation and induce apoptosis. Recently, more clinical studies have reported that TXT combined with gemcitabine (GEM) is effective in the treatment of OS (relapse/refractory and progressive), providing evidence in support of potential novel treatment strategies for this patient population. However, there is still no global consensus on this type of chemotherapy approach. The present review summarizes current studies surrounding progress in the chemotherapeutic treatment of OS and discusses the advantages and potential feasibility of TXT+GEM in the treatment of OS.
基金:
Joint Special Funds for the Department of Science and Technology of Yunnan Province-Kunming Medical University [2014FB059, 2018NS0069, 2018NS0070]
第一作者机构:[1]Department of Orthopedics, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, Yunnan 650118
通讯作者:
通讯机构:[*1]Department of Orthopedics, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, 519 Kunzhou Road, Kunming, Yunnan 650118, P.R. China
推荐引用方式(GB/T 7714):
Zhang Ya,Yang Jingqing,Zhao Na,et al.Progress in the chemotherapeutic treatment of osteosarcoma[J].ONCOLOGY LETTERS.2018,16(5):6228-6237.doi:10.3892/ol.2018.9434.
APA:
Zhang, Ya,Yang, Jingqing,Zhao, Na,Wang, Cao,Kamar, Santosh...&Yang, Zuozhang.(2018).Progress in the chemotherapeutic treatment of osteosarcoma.ONCOLOGY LETTERS,16,(5)
MLA:
Zhang, Ya,et al."Progress in the chemotherapeutic treatment of osteosarcoma".ONCOLOGY LETTERS 16..5(2018):6228-6237